J Korean Med Assoc.  2006 Feb;49(2):150-162. 10.5124/jkma.2006.49.2.150.

Treatment of Psoriasis

• Youn JI

• KMID: 2184663
• DOI: http://doi.org/10.5124/jkma.2006.49.2.150

Abstract

Psoriasis is a common, chronic skin disease. The goal of therapy is always to use the appropriate medication to achieve the desired effect while minimizing side effect. The three types of traditional therapies for treatment of psoriasis are topical therapies, phototherapies and systemic therapies. Topical steroid, vit D derivatives are frequently prescribed with other agents. Broad band UVB, PUVA and narrow band UVB therapies are most commonly used phototherapy. Three main systemic agents now used for moderate to severe psoriasis are retinoid, cyclosporine and methotrexate. Psoriasis is recently found to be an T-cell mediated immunologic disease. This lead to the developing new targeted immunobiologic agents.The newer biologic agents appear to combine greater efficacy of treatments with less toxicity by targeting T cell activation or specific mediator, TNF-alpha.

Keyword

Psoriasis; Phototherapy; Retinoid; Cyclosporine; Biologics

MeSH Terms

Biological Factors
Biological Products
Cyclosporine
Immune System Diseases
Methotrexate
Phototherapy
Psoriasis*
Skin Diseases
T-Lymphocytes
Tumor Necrosis Factor-alpha
Biological Factors
Biological Products
Cyclosporine
Methotrexate
Tumor Necrosis Factor-alpha

Reference

2. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002. 46:1–23.

3. Dubertret L. Psoriasis from clinic to therapy. 2005. 1st ed. Paris: Medcom;61–65.

4. Seville RH. Advances in the use of anthralin. J Am Acad Dermatol. 1981. 5:319–321.

5. Montes LF, Wilborn WH, Brody I. Low strength anthralin in Psoriasis. J Cutan Pathol. 1979. 6:445–456.

6. Farber EM, Abel EA, Charuworn A. Recent advances in the treatment of psoriasis. J Am Acad Dermatol. 1983. 8:311–321.

7. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001. 2:95–120.

8. Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol. 1999. 16:321–325.

9. Langner A, Verjans H, Sfapor V, Molt M. 1α, 25-dihydroxy vitamin D3 (Clcitriol) ointment in psoriasis. J Dermatol Treat. 1992. 3:177–180.

11. Marks R. The role of tazarotene in the treatment of psoriasis. Brit J Dermatol. 1999. 140:Suppl. 24–28.

12. LeVine MJ, White HA, Parrish JA. Components of the Goeckerman regimen. J Invest Dermatol. 1979. 73:170–173.

13. Ingram JT. The approach to psoriasis. Br Med J. 1953. 2:591–594.

14. LeVine MJ, Parrish JA. Outpatient phototherapy of psoriasis. Arch Dermatol. 1980. 116:552–554.

15. Parrish JA, Fitzapatrick TB, Tannenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. New Eng J Med. 1974. 291:1207–1211.

16. British Photodermatology Group guidelines for PUVA. Br J Dermatol. 1994. 130:246–255.

17. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol. 1988. 91:120–124.

18. Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol. 1981. 76:359–362.

19. Van Weelden H, Faille B, Young E, Van der Leun JC. A new development in UVB phototherapy of psoriasis. Brit J Dermatol. 1988. 119:11–19.

20. Walters IB, Burack LH, Coven TR, Gilleaudean P, Krueger G. Suberythemogenic narrow band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol. 1999. 40:893–900.

21. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991. 24:591–594.

22. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998. 39:464–475.

23. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. systemic therapies. J Am Acad Dermatol. 2001. 45:649–661.

24. Roenigk HH Jr, Maibach HI, Weinstein GD. Guidelines on methotrexate therapy for psoriasis. Arch Dermatol. 1972. 105:363–365.

25. Roenigk HH Jr, Maibach HI, Weinstein GD. Methotrexate therapy for psoriasis: guideline revisions. Arch Dermatol. 1973. 108:36–42.

26. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate guidelines-revised. J Am Acad Dermatol. 1982. 6:145–155.

27. Sterry W, Barker J, Boehncke WH, Boss JD, Chimenti S, Voorhees . Biological therapy in the systemic managements of psoriasis: International consensus conference. Brit J Dermatol. 2004. 151:3–17.

28. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CEM. An international, randomized, double blind, placebo controlled phase 3 trial of intramuscular alephacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003. 139:719–727.

29. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldmann SR, Gottlieb AB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol. 2005. 52:425–433.

30. Goffe B, Cather JC. Etanercept : An overview. J Am Acad Dermatol. 2003. 49:S105–S111.

31. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: a randomised trial. Lancet. 2001. 357:1842–1847.